Neumann Capital Management LLC Lowers Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Neumann Capital Management LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,490 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Gilead Sciences makes up approximately 1.5% of Neumann Capital Management LLC’s portfolio, making the stock its 17th biggest position. Neumann Capital Management LLC’s holdings in Gilead Sciences were worth $4,425,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of GILD. Davis Investment Partners LLC acquired a new position in shares of Gilead Sciences in the 1st quarter worth approximately $533,000. Sapient Capital LLC raised its position in Gilead Sciences by 7,067.8% in the first quarter. Sapient Capital LLC now owns 185,360 shares of the biopharmaceutical company’s stock valued at $20,770,000 after purchasing an additional 182,774 shares during the period. Fifth Third Bancorp lifted its stake in Gilead Sciences by 25.9% during the first quarter. Fifth Third Bancorp now owns 369,101 shares of the biopharmaceutical company’s stock worth $41,358,000 after purchasing an additional 76,007 shares in the last quarter. Simon Quick Advisors LLC boosted its position in shares of Gilead Sciences by 44.3% during the first quarter. Simon Quick Advisors LLC now owns 8,834 shares of the biopharmaceutical company’s stock worth $990,000 after buying an additional 2,714 shares during the period. Finally, Zhang Financial LLC raised its holdings in shares of Gilead Sciences by 62.5% in the 1st quarter. Zhang Financial LLC now owns 3,909 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 1,503 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GILD. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Bank of America boosted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Finally, Wells Fargo & Company boosted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Trading Down 0.7%

NASDAQ GILD opened at $109.30 on Thursday. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The firm has a market cap of $135.96 billion, a PE ratio of 295.41, a P/E/G ratio of 0.71 and a beta of 0.29. The firm’s fifty day moving average is $105.40 and its two-hundred day moving average is $101.91. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm’s revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 43,000 shares of company stock valued at $4,630,310 over the last quarter. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.